Physician profile
Daniel Strait
NPI 1740274273
$1,880.00
in general payments reported to CMS, 2019-2025
19 companies · $248 in 2025
The $248 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $241 · 2020: $124 · 2021: $129 · 2022: $372 · 2023: $369 · 2024: $398 · 2025: $248.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,015.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,015.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $253.64 | 2022-2025 | Cequa |
| Alcon Vision LLC | $252.18 | 2019-2025 | Rocklatan, Precision7, Simbrinza |
| Oyster Point Pharma, INC. | $227.22 | 2023-2025 | Tyrvaya, Ryzumvi |
| Bausch & Lomb Americas INC. | $220.36 | 2022-2025 | Miebo, Vyzulta, Xiidra |
| Novartis Pharmaceuticals Corporation | $214.14 | 2019-2023 | |
| Johnson & Johnson Vision Care, INC. | $104.68 | 2019-2022 | |
| Abbvie INC. | $96.86 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $93.94 | 2019-2021 | |
| Kala Pharmaceuticals, INC. | $61.37 | 2019-2021 | |
| Harrow Eye, LLC | $53.87 | 2024 | Vevye |
| Allergan, INC. | $53.78 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $52.89 | 2024-2025 | Xdemvy |
| Coopervision INC. | $40.17 | 2019-2022 | |
| Thea Pharma INC. | $38.79 | 2023-2025 | Iyuzeh |
| Biotissue Holdings INC. | $34.54 | 2020-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $21.37 | 2019 | |
| Sight Sciences, INC. | $20.68 | 2022 | |
| Amgen INC. | $20.60 | 2024 | Tepezza |
| Eyevance Pharmaceuticals LLC | $18.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Strait listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.